Semax is one of the most extensively studied nootropic peptides in the world, yet most people outside of Russia have never heard of it. Developed at Moscow's Institute of Molecular Genetics in the 1980s, it's been a registered pharmaceutical there since the early 2000s, prescribed for stroke recovery, cognitive disorders, and optic nerve conditions.

The peptide is a synthetic fragment of adrenocorticotropic hormone (ACTH), specifically the 4–7 amino acid sequence with an added proline-glycine-proline tail for enzymatic stability. Unlike its parent hormone, Semax doesn't affect cortisol or adrenal function. Its effects are concentrated entirely on the brain: enhancing neurotrophic factor expression, modulating neurotransmitter activity, and improving cerebral blood flow.

Semax at a Glance

Semax was originally developed as a treatment for stroke and cognitive disorders, conditions where its ability to protect and regenerate neurons had clear clinical value. Over time, its nootropic properties attracted attention from researchers and biohackers worldwide. Today it occupies a unique position: a peptide with genuine pharmaceutical credentials in one country and research-chemical status everywhere else.

For a deeper compound profile, visit PeptideArc.

How Semax Works: Four Core Mechanisms

Semax acts on multiple neurobiological pathways simultaneously, which is partly why it produces such a broad range of cognitive and neuroprotective effects. Understanding these mechanisms helps explain why it's useful for both acute cognitive enhancement and long-term brain health.

BDNF and NGF Upregulation

This is the mechanism that defines Semax. Brain-Derived Neurotrophic Factor (BDNF) drives the growth of new neurons, strengthens existing synaptic connections, and supports long-term memory formation. Nerve Growth Factor (NGF) is critical for the survival and maintenance of cholinergic neurons, the cells most directly involved in memory and learning.

Studies show Semax can increase BDNF mRNA expression by several fold in the hippocampus and cortex, the brain regions responsible for memory consolidation and executive function (Dolotov et al., 2006). What makes this particularly compelling is that the neurotrophic effects persist beyond the dosing period. This suggests Semax triggers lasting structural changes in brain circuitry rather than just temporary chemical shifts.

Neurotransmitter Modulation

Semax influences dopamine, serotonin, and norepinephrine activity in the brain. This triple-neurotransmitter effect contributes to the improved motivation, mood stability, and mental alertness that users commonly report. It doesn't flood the brain with any single neurotransmitter the way stimulants do. Instead, it modulates receptor sensitivity and turnover rates, producing a more balanced and sustainable effect.

Enkephalinase Inhibition

The peptide temporarily inhibits enzymes that break down enkephalins, the body's natural stress-buffering opioids. By preserving endogenous enkephalins, Semax enhances stress resilience without producing sedation or euphoria. This mechanism is distinct from the way benzodiazepines or SSRIs work, and it carries no known dependence risk (Ashmarin et al., 1995).

Cerebral Blood Flow

Semax improves circulation and oxygen delivery to brain tissue. Neurons are metabolically demanding cells, and even small improvements in blood supply can translate to meaningful gains in processing speed and sustained attention. This vascular effect is one reason it was originally developed for stroke recovery.

What Semax Actually Does: Benefits by Evidence Level

Semax Variants: Standard vs. N-Acetyl vs. NASA

Three variants exist, each with different potency and stability profiles. The chemical modifications affect how quickly the peptide is broken down by enzymes, which determines how long it remains active in the body.

Dosing Protocols

Intranasal Dosing (Preferred Route)

The intranasal route is preferred because the nasal mucosa provides a relatively direct pathway to the brain, bypassing the blood-brain barrier. Split your daily dose between both nostrils. Tilt your head slightly forward when spraying (not backward) so the solution contacts the nasal lining rather than dripping down your throat.

Subcutaneous Dosing

Timing: Morning and early afternoon doses align with peak cognitive demands. Avoid evening dosing if sleep interference is a concern. Semax typically comes as lyophilized powder requiring reconstitution with bacteriostatic water. See our reconstitution guide for instructions.

Clinical Research: What the Evidence Actually Shows

Semax has been the subject of extensive research, primarily in Russia, where it holds pharmaceutical status. The clinical applications go well beyond general cognitive enhancement.

Stroke Recovery

Patients receiving intranasal Semax showed faster recovery of motor function, speech, and cognitive ability compared to control groups. The neuroprotective effects are attributed to its combined action on BDNF, blood flow, and inflammatory pathways (Gusev et al., 1997).

Cognitive Disorders

Clinical studies have explored Semax in patients with cognitive impairment and early-stage dementia. Results indicate improvements in attention, working memory, and executive function. These benefits align with what healthy users report anecdotally, though the magnitude of effect tends to be more pronounced in cognitively impaired populations.

Optic Nerve Conditions

One of the more surprising research findings involves Semax's effects on visual function. Studies in patients with optic nerve atrophy showed improvements in visual acuity and visual field, likely driven by NGF-mediated support of optic nerve neurons (Polunin et al., 2000).

Semax vs. Selank: The Classic Comparison

These two Russian nootropic peptides are frequently discussed together, and for good reason. They complement each other well but serve fundamentally different primary purposes.

Stacking Semax With Other Compounds

Semax's mechanisms make it a strong candidate for stacking. The goal is choosing compounds that complement its action or address areas it doesn't primarily cover.

Side Effects and Safety

Semax has a favorable safety profile backed by decades of clinical use in Russia. Most users experience no side effects at recommended doses. When side effects do occur, they tend to be mild and transient.

Cycling Protocols

Semax doesn't produce tolerance in the traditional sense, but cycling is recommended to maintain peak responsiveness and allow natural neurochemistry to recalibrate between periods of use.

If you notice effects diminishing at your usual dose, that's a signal to initiate a break rather than increase the dose. For broader cycling strategies, see our peptide cycling guide.

Who Might Benefit

Legal Status and Sourcing

When sourcing Semax, look for vendors who provide third-party testing with HPLC and mass spectrometry verification. Purity matters significantly with peptides, and low-quality products can be ineffective or contaminated. Check our peptide legality guide for full details and our vendor red flags guide for sourcing tips.

Frequently Asked Questions

The Bottom Line

The main limitation is that most research comes from Russian institutions, and large-scale Western clinical trials are lacking. That said, the existing evidence is consistent and the mechanism of action (primarily BDNF and NGF upregulation) is well-understood and biologically plausible. For anyone serious about nootropic peptides, Semax deserves serious consideration.

Start with the standard form intranasally. Cycle responsibly. Source from a reputable vendor with third-party testing. And if you want the full nootropic peptide experience, consider pairing it with Selank for a cognitive profile that's hard to match with any other compound class.

References

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed
Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and glycine, and possessing nootropic properties. Neurosci Res Commun. 1995;16(2):105-112. PubMed
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PubMed
Polunin GS, Nurieva SM, Baiandin DL, et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15-18. PubMed
Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PubMed

Related reading:

Selank: The Anxiolytic Peptide Guide  ·  Cognition Stack: Semax, Selank, and Dihexa  ·  Dihexa Nootropic Guide  ·  Cerebrolysin Neuropeptide Guide  ·  Beginner's Guide to Peptides

For compound profiles and sourcing info, visit PeptideArc.